Tempus AI (NASDAQ:TEM) Trading 11.3% Higher - What's Next?

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report)'s stock price traded up 11.3% during trading on Friday . The company traded as high as $46.07 and last traded at $46.94. 4,486,208 shares traded hands during trading, a decline of 8% from the average session volume of 4,902,042 shares. The stock had previously closed at $42.17.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. JPMorgan Chase & Co. downgraded Tempus AI from an "overweight" rating to a "neutral" rating and increased their target price for the stock from $50.00 to $55.00 in a report on Tuesday, February 25th. Wolfe Research downgraded Tempus AI from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 26th. Piper Sandler reduced their target price on Tempus AI from $70.00 to $55.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. TD Cowen reaffirmed a "buy" rating and set a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Finally, Bank of America raised their price target on Tempus AI from $54.00 to $60.00 and gave the stock a "neutral" rating in a report on Monday, March 3rd. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $61.18.

Tempus AI Stock Performance

The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The firm has a 50-day moving average of $55.15 and a 200 day moving average of $51.92.

Insider Activity at Tempus AI

In other news, CEO Eric P. Lefkofsky sold 562,345 shares of Tempus AI stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $50.93, for a total transaction of $28,640,230.85. Following the transaction, the chief executive officer now directly owns 9,457,283 shares in the company, valued at approximately $481,659,423.19. This trade represents a 5.61 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Bradley A. Keywell sold 265,000 shares of Tempus AI stock in a transaction on Friday, January 17th. The shares were sold at an average price of $35.10, for a total value of $9,301,500.00. Following the transaction, the insider now owns 15,218,365 shares in the company, valued at approximately $534,164,611.50. This trade represents a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,755,906 shares of company stock worth $322,788,693 in the last three months.

Hedge Funds Weigh In On Tempus AI

Several hedge funds have recently modified their holdings of TEM. GSA Capital Partners LLP acquired a new position in shares of Tempus AI during the 3rd quarter valued at $306,000. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Tempus AI by 1,591.2% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company's stock worth $68,922,000 after acquiring an additional 1,145,698 shares during the last quarter. First Horizon Advisors Inc. acquired a new position in shares of Tempus AI in the 3rd quarter worth $30,000. The Manufacturers Life Insurance Company grew its holdings in shares of Tempus AI by 10.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company's stock worth $1,686,000 after acquiring an additional 2,765 shares during the last quarter. Finally, Captrust Financial Advisors acquired a new position in shares of Tempus AI in the 3rd quarter worth $2,726,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads